Company intelligence / Profile preview

Tiamat Sciences

Durham, North Carolina, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Tiamat Sciences developed a proprietary plant-based system to produce animal-free recombinant proteins—including growth factors and cytokines—for applications in regenerative medicine, vaccine development, cell culture media, and biotechnology. No clinical trial results reported; company focused on supplying reagents rather than developing its own therapeutics.

Therapeutic areas: Infectious DiseasesOther
Modalities: Recombinant proteinProteinCytokineEnzymeGrowth factor protein
Industry: Chemicals & Materials

Beyond the preview

Go deeper on Tiamat Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiamat Sciences.

Explore the full profile